Takeda and Protagonist Therapeutics have jointly submitted a new drug application (NDA) seeking approval from the US Food and ...

Takeda and Protagonist Therapeutics have submitted a new drug application to the FDA for rusfertide for adults with ...

OSAKA, Japan & CAMBRIDGE, Mass. & NEWARK, Calif., January 05, 2026--Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist") announced the submission of a New Drug ...

One way Takeda lives out its values is by striving to ensure that patients are aware of and can access the company’s clinical ...

Takeda Pharmaceutical Co. announced that its oral psoriasis drug zasocitinib proved safe and effective in late-stage trials, marking a milestone in its effort to treat the incurable skin condition and ...

XOMA Royalty (XOMA) and Takeda (TAK) stock in focus as the companies ink a new royalty deal and armed an existing agreement.

Takeda regains a majority of XOMA Royalty’s royalty interest in mezagitamab (TAK-079) –– XOMA Royalty will be entitled to payments based on a ...

Takeda kicked off 2024 by reeling in an approval for HyQvia in chronic inflammatory demyelinating polyneuropathy (CIDP), and it’s closing out the year by launching its first direct-to-consumer ...

Takeda’s $300 million bet on Protagonist Therapeutics’ hematology asset a year ago appears to have paid off as the drug reduced blood procedures among patients with a rare type of cancer in a phase 3 ...

Takeda Pharmaceutical struck one of the biggest life science deals of 2022, acquiring a clinical-stage Nimbus Therapeutics drug addressing a promising new target for autoimmune disorders. Other than ...

Shares more than doubled in value after Phase 3 results suggested Alumis’ pill may compare favorably with other emerging oral ...

The following excerpts are from a written Q&A with Costa Saroukos, global CFO of pharmaceutical leader Takeda, since 2018. They have been lightly edited for clarity and length. How Do You Rate ...